6 free, board-style Internal Medicine End of Rotation questions — each with the correct answer and a complete explanation. No email, no account required.
Mapped to the clinician-reviewed FirstPassPA bank and the 2026 PAEA Internal Medicine blueprint. Attempt each one before you reveal the answer.
Question 1EndocrineMedium
A 62-year-old postmenopausal woman on levothyroxine 88 mcg daily for primary hypothyroidism has a TSH of 0.2 mIU/L with a normal free T4. She feels well and has no symptoms. Which of the following is the most appropriate next step?
ASwitch to desiccated thyroid extract
BContinue current dose
CDecrease levothyroxine dose
DIncrease levothyroxine dose
EAdd liothyronine
Reveal answer & full explanation
Correct answer: C — Decrease levothyroxine dose
ASwitch to desiccated thyroid extract
BContinue current dose
CDecrease levothyroxine dose✓
DIncrease levothyroxine dose
EAdd liothyronine
Why Decrease levothyroxine dose is correct
A suppressed TSH on levothyroxine increases the risk of atrial fibrillation and bone loss in postmenopausal women
The goal of levothyroxine replacement for hypothyroidism is a TSH within the reference range (about 0.4–4.0 mIU/L); this patient's TSH of 0.2 mIU/L is below it, and the ATA advises avoiding a subnormal TSH, especially in older and postmenopausal women, so reducing the dose is appropriate
Why the others are wrong
Add liothyronine — combination T3/T4 therapy is not routinely recommended and would not correct the over-replacement (trap)
Switch to desiccated thyroid extract — supraphysiologic T3 content and no advantage over levothyroxine; does not address the suppressed TSH (trap)
Increase levothyroxine dose — would further suppress TSH and worsen the risk of atrial fibrillation and bone loss (trap)
Continue current dose — tempting because she is asymptomatic with a normal free T4, but a subnormal TSH on levothyroxine is iatrogenic subclinical hyperthyroidism and still raises the risk of atrial fibrillation and bone loss (trap)
Question 2GastrointestinalMedium
A 22-year-old man is admitted to the internal medicine service after his second episode in 3 months of colicky periumbilical pain with vomiting that resolved on its own. He was adopted, and his biological family history is unknown. Hemoglobin is 9.6 g/dL, mean corpuscular volume is 72 fL, ferritin is 6 ng/mL, and stool is guaiac positive. CT obtained during the pain showed a transient jejunojejunal intussusception with a 2.5-cm intraluminal polyp at its lead point. Colonoscopy 2 days ago found only two small colonic polyps; pathology is pending. He is now pain free, and his vital signs are normal. Which additional physical examination finding is most likely?
ADiffuse uniform darkening of the palmar creases and the gums
BClusters of small dark-brown macules on lips and inner cheeks
CHard, painless bony swelling along the angle of the mandible
DSix or more oval tan patches over 1.5 cm with axillary freckling
ESeveral yellow-tan papules and nodules on the face and trunk
Reveal answer & full explanation
Correct answer: B — Clusters of small dark-brown macules on lips and inner cheeks
ADiffuse uniform darkening of the palmar creases and the gums
BClusters of small dark-brown macules on lips and inner cheeks✓
CHard, painless bony swelling along the angle of the mandible
DSix or more oval tan patches over 1.5 cm with axillary freckling
ESeveral yellow-tan papules and nodules on the face and trunk
Why Clusters of small dark-brown macules on lips and inner cheeks is correct
A young adult with recurrent small-bowel intussusception whose lead point is a large jejunal polyp, plus iron deficiency anemia from occult bleeding, points to Peutz-Jeghers syndrome, an autosomal dominant hamartomatous polyposis in which polyps cluster in the small bowel (jejunum most of all).
Its skin and mucosa marker is discrete, small (1-5 mm) dark-brown to blue-gray macules on the lips and buccal mucosa, often also around the mouth, nose and eyes and on the fingers and toes. Lip and skin macules may fade after puberty, but buccal pigment usually persists, so the inner cheeks are the place to look in an adult.
With the family history unavailable, the examination carries the diagnosis. Under the 2022 US Multi-Society Task Force on Colorectal Cancer (USMSTF) statement on gastrointestinal (GI) hamartomatous polyposis syndromes (Boland et al.), once the lead-point polyp is histologically confirmed as a Peutz-Jeghers polyp, Peutz-Jeghers polyps plus characteristic mucocutaneous pigmentation meet a clinical criterion for the syndrome. The polyp has not been resected yet, so the pigment supports the syndrome but is not a diagnosis on its own; germline STK11 testing is recommended.
Why the others are wrong
Hard, painless bony swelling along the angle of the mandible - Mandibular osteomas mark the Gardner variant of familial adenomatous polyposis (FAP), which produces hundreds to thousands of colorectal adenomas by early adulthood; a colonoscopy with only two small polyps argues against it, and a large jejunal polyp causing recurrent intussusception is not how FAP presents (the trap is reaching for the best-known polyposis syndrome).
Six or more oval tan patches over 1.5 cm with axillary freckling - These are the cafe-au-lait macules and skin-fold freckling of neurofibromatosis type 1 (NF1), found on the trunk and in the folds rather than on the lips or buccal mucosa; NF1 GI tumors, such as a gastrointestinal stromal tumor (GIST) or neurofibroma, arise beneath the mucosa, usually appear in middle age, and are not a hamartomatous polyposis (the trap is equating any pigmented macules or freckling with this syndrome).
Several yellow-tan papules and nodules on the face and trunk - Multiple sebaceous neoplasms, especially sebaceous adenomas and those arising off the head and neck such as on the trunk, suggest Muir-Torre syndrome, a Lynch syndrome variant; Lynch syndrome is not a polyposis syndrome, its colorectal and small-bowel cancers and its sebaceous tumors usually appear in middle age, and it is not expected to produce a large jejunal polyp that repeatedly telescopes in a 22-year-old (the trap is reaching for a hereditary colorectal cancer syndrome because a polyp was found).
Diffuse uniform darkening of the palmar creases and the gums - Diffuse, adrenocorticotropic hormone (ACTH)-driven pigmentation of the creases, gingiva and buccal mucosa suggests primary adrenal insufficiency (Addison disease), an endocrine disorder with no link to GI polyps, intussusception or occult GI bleeding (the trap is treating any oral pigmentation as the same sign; this syndrome's pigment is discrete macules, not diffuse darkening).
Additional high-yield points
Contrast the pigment patterns: discrete small macules on the lips and buccal mucosa (Peutz-Jeghers) versus diffuse darkening of the buccal mucosa, gums and palmar creases (Addison disease); cafe-au-lait macules with skin-fold freckling mark NF1.
Peutz-Jeghers syndrome carries a high lifetime cancer risk, including colorectal, gastric, small-bowel, pancreatic and breast cancer, so the 2022 USMSTF statement and the National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric guideline (2025/2026) call for scheduled upper endoscopy, colonoscopy and small-bowel imaging, plus pancreatic surveillance and, in women, breast surveillance in adulthood.
Large small-bowel polyps are removed electively (for example by device-assisted enteroscopy) to prevent intussusception and emergency laparotomy; first-degree relatives are offered genetic counseling and testing once a pathogenic variant is found.
Question 3CardiovascularHard
A 38-year-old man presents for evaluation after his 42-year-old brother died suddenly of a myocardial infarction. The patient has tendon xanthomas on both Achilles tendons and a corneal arcus. His father died of an MI at age 45. Fasting lipid panel shows total cholesterol 412 mg/dL, LDL-C 328 mg/dL, HDL-C 48 mg/dL, and triglycerides 142 mg/dL. He has no diabetes, hypothyroidism, or nephrotic syndrome. Which of the following is the most appropriate next step in management?
ABegin a 6-month trial of dietary modification before pharmacotherapy
BInitiate high-intensity statin therapy and refer for genetic testing
CInitiate ezetimibe monotherapy and recheck in 3 months
DOrder coronary angiography before any lipid-lowering therapy
EInitiate moderate-intensity statin therapy and recheck in 3 months
Reveal answer & full explanation
Correct answer: B — Initiate high-intensity statin therapy and refer for genetic testing
ABegin a 6-month trial of dietary modification before pharmacotherapy
BInitiate high-intensity statin therapy and refer for genetic testing✓
CInitiate ezetimibe monotherapy and recheck in 3 months
DOrder coronary angiography before any lipid-lowering therapy
EInitiate moderate-intensity statin therapy and recheck in 3 months
Why Initiate high-intensity statin therapy and refer for genetic testing is correct
This patient has heterozygous familial hypercholesterolemia (HeFH), suggested by markedly elevated LDL-C above 190 mg/dL, tendon xanthomas, corneal arcus before age 45, and a strong family history of premature coronary disease and sudden cardiac death
HeFH is most often caused by loss-of-function mutations in the LDL receptor (also APOB or gain-of-function PCSK9), reducing hepatic LDL clearance
Untreated HeFH carries up to a 20-fold increased risk of premature coronary disease
High-intensity statin therapy (atorvastatin 40–80 mg or rosuvastatin 20–40 mg) should be started immediately
His goals under the 2026 ACC/AHA dyslipidemia guideline (LDL-C ≥190 mg/dL with heterozygous FH and no clinical ASCVD) are LDL-C <70 mg/dL and non-HDL-C <100 mg/dL; if they and a reduction of at least 50% are not reached on a maximally tolerated statin, add ezetimibe, a PCSK9 monoclonal antibody, or bempedoic acid
Genetic testing and cascade screening of first-degree relatives are recommended
Why the others are wrong
Begin a 6-month trial of dietary modification before pharmacotherapy — a prolonged diet-only trial inappropriately delays therapy in this very high-risk patient; lifestyle changes are adjunctive, not primary
Initiate ezetimibe monotherapy and recheck in 3 months — ezetimibe alone lowers LDL-C only about 15–20% and is an add-on to statin therapy, so it cannot approach the at least 50% reduction this patient needs and leaves an LDL-C of 328 mg/dL largely untreated for 3 months
Order coronary angiography before any lipid-lowering therapy — coronary angiography is not indicated in an asymptomatic patient without ischemic symptoms or abnormal noninvasive testing, and lipid therapy should never be delayed pending it
Initiate moderate-intensity statin therapy and recheck in 3 months — a statin is the right drug class, but LDL-C ≥190 mg/dL with suspected HeFH calls for high-intensity therapy from the start; a moderate-intensity statin lowers LDL-C only about 30–49%, short of the at least 50% reduction he needs, and waiting 3 months to step up leaves a very high-risk patient undertreated
Question 4NeurologyMedium
A 57-year-old man recovering from an ischemic stroke is preparing for discharge. He smokes cigarettes daily and asks for help quitting. He has no contraindication to standard cessation medications. Which prevention plan follows the United States Preventive Services Task Force (USPSTF) 2021 recommendation for nonpregnant adults aged 18 years or older?
AProvide electronic cigarettes as the preferred first cessation method
BProvide behavioral counseling and offer approved cessation medication
CProvide a plan to switch to lower-nicotine cigarettes before quitting
DProvide varenicline and defer counseling until after rehabilitation
EProvide cessation medication only after counseling has repeatedly failed
Reveal answer & full explanation
Correct answer: B — Provide behavioral counseling and offer approved cessation medication
AProvide electronic cigarettes as the preferred first cessation method
BProvide behavioral counseling and offer approved cessation medication✓
CProvide a plan to switch to lower-nicotine cigarettes before quitting
DProvide varenicline and defer counseling until after rehabilitation
EProvide cessation medication only after counseling has repeatedly failed
Why Provide behavioral counseling and offer approved cessation medication is correct
Continued smoking is a modifiable vascular risk in this adult stroke survivor.
Behavioral support and pharmacotherapy address behavioral reinforcement and nicotine dependence.
USPSTF 2021 gives a Grade A recommendation to counseling and approved pharmacotherapy for nonpregnant adults who smoke.
Why the others are wrong
Provide varenicline and defer counseling until after rehabilitation - USPSTF recommends behavioral interventions together with pharmacotherapy, and the combination achieves higher quit rates than either alone; counseling should not be postponed.
Provide a plan to switch to lower-nicotine cigarettes before quitting - Lower-nicotine cigarettes are not an FDA-approved cessation treatment, and smokers often compensate by smoking more intensely.
Provide cessation medication only after counseling has repeatedly failed - Medication does not require prior failure of repeated counseling attempts.
Provide electronic cigarettes as the preferred first cessation method - USPSTF found insufficient evidence to recommend electronic cigarettes for cessation.
Additional high-yield points
Arrange follow-up support after discharge, including a quitline if useful.
Select medication collaboratively based on contraindications, prior experience, and patient preference.
Question 5HematologyHard
A 48-year-old man has had 2 unprovoked deep vein thromboses (DVTs) in 3 years. He is heterozygous for Factor V Leiden. He completed 6 months of anticoagulation after his last DVT. Which of the following is the most appropriate long-term management?
AAnticoagulation only during high-risk periods (surgery, immobilization, prolonged travel)
BNo further anticoagulation
CIndefinite anticoagulation with a direct oral anticoagulant (DOAC)
DInferior vena cava (IVC) filter placement
EIndefinite low-dose aspirin therapy
Reveal answer & full explanation
Correct answer: C — Indefinite anticoagulation with a direct oral anticoagulant (DOAC)
AAnticoagulation only during high-risk periods (surgery, immobilization, prolonged travel)
BNo further anticoagulation
CIndefinite anticoagulation with a direct oral anticoagulant (DOAC)✓
DInferior vena cava (IVC) filter placement
EIndefinite low-dose aspirin therapy
Why Indefinite anticoagulation with a direct oral anticoagulant (DOAC) is correct
Recurrent unprovoked venous thromboembolism (VTE) — two or more episodes without a provoking factor — is an indication for indefinite anticoagulation regardless of thrombophilia status
The risk of recurrence after a second unprovoked VTE exceeds 40% at 5 years
DOACs (rivaroxaban, apixaban) are preferred
Why the others are wrong
Anticoagulation only during high-risk periods (surgery, immobilization, prolonged travel) — intermittent prophylaxis does not protect against recurrent unprovoked events, which occur without a trigger (trap)
No further anticoagulation — leaves a patient with a >40% 5-year recurrence risk unprotected (trap)
Inferior vena cava (IVC) filter placement — reserved for patients who cannot be anticoagulated; it does not treat the thrombophilic state and carries its own thrombotic risk (trap)
Indefinite low-dose aspirin therapy — aspirin modestly reduces recurrence when anticoagulation is stopped, but it is much less effective than continued anticoagulation, which is indicated indefinitely after a second unprovoked VTE unless bleeding risk is high (trap)
Additional high-yield points
Factor V Leiden heterozygosity alone does not mandate indefinite anticoagulation after a first unprovoked VTE, but after a second event the decision is clear
Question 6RenalMedium
A 60-year-old man with chronic kidney disease (CKD) (eGFR 22) is admitted for pneumonia. Potassium is 6.2 mEq/L and ECG shows peaked T waves. Which of the following is the most appropriate first step in management?
AEmergent hemodialysis
BSodium polystyrene sulfonate orally
CIV calcium gluconate
DIV furosemide
EIV regular insulin with dextrose
Reveal answer & full explanation
Correct answer: C — IV calcium gluconate
AEmergent hemodialysis
BSodium polystyrene sulfonate orally
CIV calcium gluconate✓
DIV furosemide
EIV regular insulin with dextrose
Why IV calcium gluconate is correct
Hyperkalemia with ECG changes (peaked T waves) is a cardiac emergency
IV calcium gluconate is given first because it stabilizes the cardiac membrane within minutes
After calcium, insulin with dextrose shifts K+ into cells, starting within about 15 minutes and peaking at about 30-60 minutes (sodium bicarbonate only if acidotic)
Oral binders (sodium polystyrene sulfonate, patiromer, sodium zirconium cyclosilicate) remove K+ too slowly for an emergency and are adjuncts only; their FDA labels say not to use them as emergency treatment of life-threatening hyperkalemia
Why the others are wrong
Sodium polystyrene sulfonate orally — sodium polystyrene sulfonate removes potassium over hours to days and is inappropriate as a first step when ECG changes are present
Emergent hemodialysis — hemodialysis is used when medical therapy fails (and early in patients already on dialysis), but it takes time to arrange and is not the first step
IV furosemide — furosemide promotes renal potassium excretion, but its effect is less reliable at an eGFR of 22 and it does not protect the heart, so it is not the first step when ECG changes are present
IV regular insulin with dextrose — insulin with dextrose shifts potassium into cells and lowers the serum level, but it does not directly stabilize the cardiac membrane and takes longer to act than calcium; with peaked T waves, calcium is given first for immediate membrane stabilization, and insulin with dextrose follows
That's 6 of 7,700+. Get the rest.
Unlock the full FirstPassPA bank — 7,700+ board-style questions, all seven EOR rotations with a focused Internal Medicine set, flashcards, and an AI tutor that explains every answer. Start your 7-day free trial — no credit card.
Are these Internal Medicine EOR practice questions free?
Yes. Every question here shows the full vignette, the correct answer, and a complete explanation with no email or account required. A free 7-day trial unlocks the full 7,700+ question bank, all seven EOR rotations, flashcards, and an AI tutor.
Are these questions aligned with the 2026 Internal Medicine EOR blueprint?
Yes. They are drawn from the clinician-reviewed FirstPassPA bank, mapped to the NCCPA/PAEA blueprint and this rotation's content areas. PAEA's updated End of Rotation exams are effective as of July 27, 2026 (Surgery moved to its rebuilt blueprint earlier); see what changed on the Internal Medicine exam on our blueprint-changes page.
How should I use these Internal Medicine EOR practice questions?
Attempt each vignette before revealing the answer, then read the full explanation even when you get it right — the reasoning for why the distractors are wrong is where most of the learning is. Then practice focused, blueprint-weighted question blocks in the app as your exam date nears.
Educational use only. These questions are a study aid for PA students and are not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.